ANGPLT3 in cardio-metabolic disorders

Area of Science:

• Biochemistry
• Genetics
• Cardiovascular Medicine

Background:

• Dyslipidemia, a key component of metabolic syndrome, significantly increases mortality and cardio-metabolic disorder risk.
• Angiopoietin-like protein (ANGPTL) family members are implicated in angiogenesis and lipid metabolism.
• ANGPTL3 is a crucial regulator of circulating lipid levels by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL).

Purpose of the Study:

• To review the role of ANGPTL3 in modulating dyslipidemia and associated cardio-metabolic disorders.
• To explore ANGPTL3 as a potential therapeutic target for metabolic syndrome.

Main Methods:

• Review of existing literature on ANGPTL3 function and its impact on lipid metabolism.
• Analysis of studies involving ANGPTL3 gene-deficiency in mice and human loss-of-function mutations.
• Synthesis of current understanding regarding ANGPTL3's role in dyslipidemia and atherosclerosis.

Main Results:

• ANGPTL3 deficiency in mice leads to reduced low-density lipoprotein cholesterol (LDL-C) and decreased atherosclerosis.
• Human genetic studies show homozygous loss-of-function mutations in ANGPTL3 are associated with lower LDL-C levels and reduced atherosclerotic risk.
• ANGPTL3 acts as a key inhibitor of LPL and EL, thereby controlling lipid catabolism.

Conclusions:

• ANGPTL3 plays a significant role in regulating lipid metabolism and cardio-metabolic health.
• Targeting ANGPTL3 presents a promising therapeutic strategy for managing dyslipidemia and metabolic syndrome.